This test is medicare rebateable as per MBS no 73322. 

P7 - Genetics

Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if:

(a) the service is requested by a specialist or consultant physician; and

(b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and

(c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity

Applicable once per lifetime

Specimen must be collected in a dedicated EDTA tube.

Sample must be in a dedicated EDTA tube.